WebGarth Rapeport CEO GLOBAL BUSINESS DEVELOPMENT Pulmocide United Kingdom Biography Garth is a medical graduate who undertook post-graduate training in General … WebAug 24, 2024 · PC945 is a novel triazole optimized for lung delivery, and the objective of this study is to determine the effects of intranasally dosed PC945 on Aspergillus fumigatus infection and associated biomarkers in immunocompromised mice. PC945, posaconazole, or voriconazole was administered intranasally once daily on days 0 to 3 (early …
Pulmocide presents clinical update from promising
WebAug 7, 2024 · Garth Rapeport is CEO of Pulmocide Ltd, a drug discovery company working on identifying new treatments for Invasive Aspergillosis and RSV and visiting Professor … WebGarth RAPEPORT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been … site la louvière
Q&A with Pulmocide CEO Garth Rapeport - SWNS
WebSep 16, 2024 · Subintro co-founder and CEO and F-Prime Capital entrepreneur-in-residence Garth Rapeport said: “At Subintro, we have been investigating a range of new approaches to maximise the cellular activity and safety of diverse antiviral agents when delivered to respiratory epithelium. WebJun 1, 2010 · Dr. Garth Rapeport, Chief Executive Officer of RespiVert, who is remaining with RespiVert following the acquisition, said, "We believe that our focused discovery efforts in pulmonary disease offer a unique opportunity to bring completely new treatment options to patients who suffer from severe, chronic respiratory diseases including Chronic … WebSep 11, 2024 · Garth Rapeport View Show abstract Standardisation of spirometry Article Full-text available Mar 2007 REV MAL RESPIR Martin Raymond Miller Jenny Hankinson Vito Brusasco J. Wanger View... pds login